For the anti-PD-L1 group, myelosuppression was the most significant signal associated with atezolizumab (ROR025: 13.20) and durvalumab (ROR025: 18.71), followed by febrile neutropenia (ROR025: 10.93 and 9.59, respectively). Here, CD274 is linked to myelosuppression.